Medical Science Liaison, Rare Diseases — Remote/Field

Chiesi Farmaceutici S.p.A. is an international, research-focused biopharmaceutical group with over 85 years of experience, headquartered in Parma, Italy. The company develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. Chiesi operates with a strong commitment to improving people's quality of life while acting responsibly towards both the community and the environment. This dedication is underscored by its status as a Benefit Corporation in Italy, the US, and France, legally binding its commitment to create shared value for society as a whole and making it central to company-wide decision-making. Since 2019, Chiesi has been a certified B Corp, joining a global community of businesses that meet high standards of social and environmental impact. The company aims to achieve Net-Zero greenhouse gas (GHG) emissions by 2035.

Founded in 1935 by Giacomo Chiesi, a chemist with a vision for research, the company has grown from a small laboratory in Parma to a global entity with a direct presence in 31 countries and distribution in over 100 nations. The Chiesi Group employs approximately 6,500 to 7,500 people worldwide. Its research and development activities are centered in Parma and integrated with six other major research hubs in France, the United States, Canada, China, the United Kingdom, and Sweden. Production facilities are located in Italy (Parma), France (Blois), and Brazil (Santana de Parnaiba). Chiesi focuses its R&D efforts on innovative drugs in its core therapeutic areas: AIR (products and services for respiratory conditions), RARE (solutions for rare and ultra-rare diseases), and CARE (products for specialist care, personal care, and well-being). The company invests a significant portion of its turnover, around 20-24%, into research and development. Chiesi's commitment to innovation is also reflected in its patent filings, being recognized as a leading Italian pharmaceutical company in this regard.